Deutsche Bank analyst George Hill downgrades Veradigm (OTC:MDRX) from Buy to Hold and lowers the price target from $15 to $10.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2024 | $15.00 → $10.00 | Buy → Hold | Deutsche Bank |
| 1/3/2024 | $11.00 | Equal Weight | Barclays |
| 7/6/2023 | Buy → Hold | Argus | |
| 4/12/2023 | $13.00 | Equal-Weight | Stephens |
| 2/1/2023 | $17.00 → $18.50 | Overweight → Neutral | Piper Sandler |
| 12/7/2022 | $26.00 | Hold → Buy | Argus |
| 11/9/2022 | $22.00 → $23.00 | Neutral → Buy | Goldman |
| 11/4/2022 | $17.00 | Overweight | Piper Sandler |
TD Cowen analyst Charles Rhyee maintains Veradigm (OTC:MDRX) with a Buy and lowers the price target from $26 to $15.
Deutsche Bank analyst George Hill downgrades Veradigm (OTC:MDRX) from Buy to Hold and lowers the price target from $15 to $10.
Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600.
NLP-enhanced data from over 154 million patient records facilitates innovation in real-world evidence research via the Veradigm Network Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the complete integration of advanced natural language processing (NLP) into its electronic health record (EHR) dataset. This integration enhances access to valuable insights from unstructured EHR data and combines it with structured data to create regulatory-grade, real-world data (RWD) that's purpose-built for research. Veradigm Network EHR Data is sourced from over 154 million unique patient records and is one of the most comprehensive ambulatory databa
The Veradigm Network continues to expand, driving value while saving time for healthcare providers and payers Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that more than 300,000 healthcare providers throughout the United States are currently using its automated medical chart retrieval solution, Veradigm eChart Courier. This milestone reflects the growing demand for solutions that improve efficiency, reduce administrative burden, and seamlessly connect healthcare providers and payers. "Manual chart chasing is time consuming and resource intensive for health plans and providers," said Tom Langan, Interim CEO, President and Chief Comm
Veradigm received top honors for End-to-End Retrospective Risk Adjustment Solutions Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, has been named the number one overall vendor by KLAS for broad retrospective vendors, according to the Risk Adjustment 2024 report. This KLAS report examined key factors influencing risk adjustment purchase decisions, noting the growing demand for risk adjustment solutions including both retrospective and prospective capabilities. Veradigm clients reported strong satisfaction with the company's comprehensive suite of solutions, ranking Veradigm as the most recommended vendor. "Veradigm understands that to succeed in toda
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13D - Veradigm Inc. (0001124804) (Subject)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
Veradigm Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today the acquisition of Koha Health, a full-service revenue cycle management (RCM) company. With this acquisition, Veradigm further adds to its depth of offerings and expertise as a leading provider of revenue cycle services in the ambulatory healthcare market. "Today's announcement represents an exciting opportunity for Veradigm to scale our revenue cycle services portfolio by leveraging additional capabilities and subject matter expertise to better serve the needs of the market," said Tom Langan, President, and Chief Commercial Officer at Veradigm. This acquisition brings additional
Veradigm®, Inc. (NASDAQ:MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Fourth-Quarter 2022 Financial Results Call Details To listen to the conference call, participants may log onto the Veradigm Investor Relations website. Participants also may access the conference call by dialing 877-269-7756 or 201-689-7817 and requesting Conference ID # 13735356. A replay of the call will be available for a period of a year on the Veradi
Veradigm Inc. (NASDAQ:MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm repurchased $57 million of its common stock, bringing its full year total to $234 million. The company also introduced initial financial guidance for Fiscal 2023 as follows: Revenue is expected between $640 million and $660
Third quarter consolidated revenue of $152 million Third quarter consolidated operating profit up over 30% year-over-year Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2022. Third quarter 2022 Veradigm revenue was $145 million compared with $137 million in the third quarter of 2021. On a consolidated Allscripts basis third quarter 2022 revenue was $152 million compared with $145 million in the third quarter of 2021. On a GAAP basis, Veradigm income from operations was $28 million in the third quarter of 202
Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously
Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00
Argus downgraded Veradigm from Buy to Hold
4/A - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
8-K - Veradigm Inc. (0001124804) (Filer)
NT 10-Q - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)